Coccidioidomycosis and COVID-19 Infection. An Analysis from a Single Medical Center Within the Coccidioidal Endemic Area

Daniel Huff · Neil M. Ampel · Janis E. Blair

Abstract At a single medical center, we identified 60 cases of coccidioidomycosis that were coincident with COVID-19 infection. Among these, seven patients developed new or clinically progressive coccidioidomycosis. Receipt of dexamethasone for COVID-19 infection was the only significant risk factor for the progression or development of clinically active coccidioidomycosis in this cohort. All patients survived and none developed disseminated coccidioidomycosis.

Keywords Coccidioidomycosis · Fungal infections · COVID-19 · SARS-CoV-2

Introduction

Infection with SARS-CoV-2 results in COVID-19, a respiratory illness of varying severity. In progressive cases involving the lower respiratory tract, infection may result in multiple pulmonary infiltrates and respiratory failure. Treatment often requires immunosuppressive medications, including corticosteroids. Because of these issues, patients with COVID-19 may be at risk for opportunistic respiratory infections, including those due to fungi [1].

Coccidioidomycosis is a fungal infection endemic to specific areas of the western and southwestern United States [2]. Infection is almost always due to inhalation of arthroconidia from the environment into the respiratory tree. It has been postulated that the COVID-19 pandemic might affect the presentation of coccidioidomycosis, including causing cases of reactivation of clinically quiescent coccidioidomycosis and association with more severe coccidioidal disease [3]. To date, there have been multiple case reports of progressive or worsening coccidioidomycosis in association with COVID-19 [4–8], but no case series or analysis of the risk of the interaction of these two respiratory infections. In this report, we examine coincident cases of coccidioidomycosis and COVID-19 from a single medical center located in the coccidioidal endemic region. Our goals were to describe such cases, determine if there were instances of progression of coccidioidomycosis, and, if so, to detail their management and outcome.
Materials and Methods

A retrospective review was conducted of the electronic health records for patients with both coccidioidomycosis and COVID-19 between January 1 and December 31, 2020 at Mayo Clinic in Arizona. Cases were identified using a search for ICD-10 codes for both infections (B38.0 – B38.9 for coccidioidomycosis; U07.1 for COVID-19).

Inclusion criteria for COVID-19 required a positive antigen or PCR test. Inclusion criteria for coccidioidomycosis required a patient to have proven or probable coccidioidomycosis, or coccidioidal seropositivity in an immunosuppressed host treated with ongoing antifungal suppression. We defined proven coccidioidomycosis as patients with a positive culture confirmed by the Hologic AccuProbe Coccidioides Immitis Culture Identification Test (Marlborough, Massachusetts), pathology or polymerase chain reaction for Coccidioides species. Probable coccidioidomycosis was defined as the presence of a positive coccidioidal serology, appropriate symptoms and typical radiographic manifestations.

Progressive coccidioidomycosis in association with COVID-19 infection was defined as coccidioidal disease deterioration manifested by an increase in the previously identified coccidioidal complement fixation (CF) titer or by progression of radiographic changes previously attributed to coccidioidomycosis.

We included patients with coccidioidomycosis prior to COVID-19, concurrent with COVID-19, and after COVID-19. Patients whose coccidioidomycosis preceded their COVID-19 were included only if the patient still had active symptoms, serology or radiographic abnormalities. We defined coccidioidomycosis as concurrent with COVID-19 when the symptoms, radiographs and serologic abnormalities of coccidioidomycosis were encountered at the time of diagnosis of COVID-19. Coccidioidomycosis after COVID-19 was defined as being diagnosed within 6 weeks after the diagnosis of COVID-19. The outcome of interest was either progression of already diagnosed coccidioidomycosis or development of clinically active coccidioidomycosis at the time or soon after COVID-19.

Statistical analysis was performed using Stata 17 (Stata Corp.). A p-value ≤ 0.05 was considered to be significant. The Mann–Whitney rank sum test was used for the analysis of age. All categorical variables were analyzed using the Chi-square test.

Results

A total of 3323 patients with coccidioidomycosis and 5959 with COVID-19 were identified during the period of study. Among these, 60 patients met the criteria of having coccidioidomycosis either prior, concurrently, or within 6 weeks after COVID-19 infection. The median age of the patients was 56 years (range 17–82) and 37 were male. One was African-American, one was Filipino, and five identified as Hispanic. Two declined to provide information on their race or ethnicity. Coccidioidomycosis involved the lungs in 54 subjects or manifested a positive antibody test in an immunosuppressed host in 3 subjects. Two had coccidioidal meningitis and one had non-meningeal disseminated coccidioidomycosis. Twenty-three patients with coccidioidomycosis were on antifungal therapy at the time of their diagnosis of COVID-19.

Clinically active coccidioidomycosis progressed or developed among seven individuals during COVID-19 infection. Patients who progressed did not differ by underlying illnesses, including tobacco use, diabetes mellitus, cancer, or pulmonary or cardiovascular disease (data not shown). Other characteristics comparing patients who progressed or developed coccidioidomycosis to those who did not are displayed in Table 1. As shown, there were no differences in age, sex, ethnicity, whether the coccidioidomycosis was prior, concurrent or after COVID-19, whether they were on antifungal therapy at the time of COVID-19 diagnosis, whether they were receiving immunosuppressive medication or were solid organ transplant (SOT) recipients. Moreover, coccidioidomycosis was no more likely to progress in those hospitalized or in those who received remdesivir or plasma or monoclonal antibody therapy. No patients received anti-cytokine therapy. However, patients who received dexamethasone as part of their COVID-19 treatment were significantly more likely to have progressive or newly diagnosed clinical coccidioidomycosis (P = 0.042).

Details regarding the seven patients whose coccidioidomycosis progressed or developed during COVID-19 infection are displayed in Table 2. Four
patients had a diagnosis of coccidioidomycosis prior to COVID-19 infection, one was diagnosed during infection, and two developed pulmonary coccidioidomycosis after COVID-19 infection. Two patients were on immunosuppression and one was an SOT recipient (liver). Six were not on antifungal therapy at the time of development of COVID-19. Five patients were hospitalized for COVID-19 and five received dexamethasone treatment, one as an outpatient.

Six patients developed increasing lung masses and rising coccidioidal complement-fixation (CF) titers while one developed a coccidioidal CF titer to 1:128 without a definable pulmonary focus. Figure 1 demonstrates the second subject in Table 1, who manifested increasing pulmonary infiltrates at the site of prior pulmonary coccidioidomycosis with typical findings of COVID-19 in other parts of the pulmonary parenchyma. All patients survived and no patient developed extrathoracic dissemination.

**Discussion**

These results indicate that coccidioidomycosis is not an uncommon coincident condition among patients with COVID-19 infection who reside in the coccidioidal endemic region. Because coccidioidomycosis and COVID-19 have many overlapping symptoms, we relied on objective markers of serologic CF titers and distinctive radiographic progression to identify coccidioidal outcomes. While in the majority of patients, coccidioidomycosis did not worsen during COVID-19, it did progress or develop either during or soon after COVID-19 in seven of the 60 patients identified. In most cases, progression appeared to be related to those with severe COVID-19 requiring hospitalization and the use of dexamethasone. No patients manifested new extrathoracic dissemination or died and all improved with antifungal therapy once coccidioidomycosis was diagnosed.

Our findings suggest that within the coccidioidal endemic region, clinicians should be alert to the possibility of progressive pulmonary coccidioidomycosis during management of COVID-19, particularly during hospitalization or when dexamethasone or other corticosteroids are used. If found, it would be prudent to initiate antifungal therapy, as recommended in the Infectious Diseases Society of America guidelines for immunocompromised patients [9]. Although we did not find that any patients in this cohort who developed extrathoracic coccidioidomycosis in

---

### Table 1 Summary description of the cohort of patients with coccidioidomycosis and COVID-19 infection

| Characteristic                              | Stable (53) | Progressed (7) | P-value |
|--------------------------------------------|-------------|----------------|---------|
| Age (median, range)                        | 55 (17–82)  | 63.5 (23–81)   | 0.185   |
| Sex                                        |             |                |         |
| Male                                       | 31          | 6              |         |
| Female                                     | 22          | 1              | 0.164   |
| Ethnicity (n = 58)                         |             |                |         |
| Non-Hispanic                               | 47          | 5              | 0.091   |
| Hispanic or Filipino                       | 4           | 2              |         |
| Occurrence of coccidioidomycosis in relation to COVID-19 |         |                |         |
| Prior                                      | 40          | 4              |         |
| Concurrent or after                        | 13          | 3              | 0.303   |
| Type of coccidioidomycosis                |             |                |         |
| Antibody only                              | 2           | 1              |         |
| Pulmonary                                  | 48          | 6              |         |
| Disseminated                               | 3           | 0              | 0.999   |
| Antifungals prior to COVID-19              |             |                |         |
| No                                         | 31          | 6              |         |
| Yes**                                      | 22          | 1              | 0.164   |
| Immunosuppressive Therapy                  |             |                |         |
| No                                         | 35          | 5              |         |
| Yes                                        | 18          | 2              | 0.776   |
| Solid organ transplant                     |             |                |         |
| No                                         | 41          | 6              |         |
| Yes                                        | 12          | 1              | 0.614   |
| Hospitalized                               |             |                |         |
| No                                         | 30          | 2              |         |
| Yes                                        | 23          | 5              | 0.162   |
| Dexamethasone                              |             |                |         |
| No                                         | 36          | 2              |         |
| Yes                                        | 17          | 5              | 0.042   |
| Remdesivir                                 |             |                |         |
| No                                         | 46          | 5              |         |
| Yes                                        | 7           | 2              | 0.285   |
| Plasma or monoclonal antibody              |             |                |         |
| No                                         | 45          | 6              |         |
| Yes                                        | 8           | 1              | 0.955   |

**Among the 25 patients on antifungal treatment at the time of COVID-19, 19 were receiving fluconazole, and 3 posaconazole. The patient whose coccidioidomycosis progressed despite antifungal treatment received isavuconazole.**
Table 2 Description of cases of coccidioidomycosis that progressed in association with COVID-19 infection

| Diagnosis* | Age | Sex | Race, ethnicity | Underlying illnesses | Coccidioidal presentation prior to COVID-19 | Antifungal therapy prior to COVID-19 | COVID-19 severity | COVID-19 course | Details of coccidioidal worsening | Management |
|------------|-----|-----|-----------------|----------------------|---------------------------------------------|---------------------------------------|------------------|-----------------|----------------------------------|------------|
| 1 Prior    | 81  | Male| White, non-hispanic | Coronary artery disease, melanoma | Stable pulmonary nodules, coccidioidal CF titer 1:2 | None | Severe | Hospitalized 11 days; received dexamethasone and remdesivir | Enlarging pulmonary nodules; coccidioidal CF increased to 1:256 | Fluconazole started and patient improved |
| 2 Prior    | 65  | Male| White, non-hispanic | Spondylitis with prednisone and TNF-α inhibitor therapy | Stable pulmonary nodule; negative coccidioidal CF titer | None | Severe | Hospitalized 8 days; received dexamethasone, remdesivir and convalescent plasma | Pulmonary infiltrate enlarged; coccidioidal CF titer increased to 1:256 | Fluconazole started and patient improved |
| 3 Prior    | 62  | Female| White, non-hispanic | Diabetes mellitus | Pulmonary cavity with coccidioidal CF titer 1:2 | Isavuconazole | Mild | No hospitalization; no ancillary therapy | Pulmonary cavity enlarged | Patient improved after resection and continued isavuconazole |
| 4 Prior    | 65  | Male| White, non-hispanic | Liver transplant | Positive coccidioidal EIA IgG only | None | Moderate | Hospitalized; received no ancillary therapy | New lung mass with positive coccidioidal serology | Fluconazole started and patient improved |
| 5 After    | 67  | Male| Filipino | Prostate cancer, non-alcoholic steatohepatitis | None | None | Severe | Hospitalized for 4 days; received dexamethasone | New pulmonary nodules and cavities with CF 1:128 two months after COVID-19 | Fluconazole started, improved |
| 6 After    | 35  | Male| White, non-hispanic | None | None | None | Moderate | No hospitalization but received dexamethasone | Developed worsening dyspnea and CF titer 1:32 within one month after COVID-19 | Fluconazole started and patient improved |
| 7 Concurrent | 45  | Male| White, hispanic | Diabetes mellitus, tobacco use | None | None | Severe | Hospitalized and received dexamethasone | Developed CF titer to 1:128 | Fluconazole started and CF declined |

*Relation of diagnosis of coccidioidomycosis to COVID19 infection
association with COVID-19, two case reports have reported this occurrence [6, 7]. In addition, other case reports noted that coccidioidomycosis was not initially recognized during COVID-19 [10, 11]. Our results and these case reports suggest that clinicians in the coccidioidal endemic area be aware of coccidioidomycosis as an acute pulmonary illness even in the midst of the COVID-19 pandemic.

This study has several limitations. The data were accrued early during the COVID-19 pandemic and before the emergence of both the delta and omicron variants of SARS-CoV-2. Because of this, results could be different today either because of infection with the newer viral variants or because of changes in therapy for COVID-19. In addition, the study was retrospective in nature and may have contained hidden and uncontrollable biases. No patients in this cohort received anti-cytokine therapy, so we cannot comment on the effect of these agents on the development of coccidioidomycosis. Finally, because the study was performed at a single medical center, results might vary with a larger and more diverse cohort.

Author Contributions Daniel Huff provided data curation and wrote an original draft; Neil M. Ampel contributed formal analysis and wrote further drafts and revisions; Janis E. Blair provided conceptualization, methodology, data curation, and wrote an original draft.

Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Declarations

Conflict of interest The authors have no relevant financial or non-financial interests to disclose.

Informed Consent This is an observational study. It was approved by the Mayo Clinic Institutional Review Board, and written informed consent was waived. The subject whose radiographic image is shown in Fig. 1 gave consent for its use.

References

1. Amin A, Vartanian A, Poladian N, Voloshko A, Yegiazaryan A, Al-Kassir AL, et al. Root causes of fungal coinfections in COVID-19 infected patients. Infect Dis Rep. 2021;13:1018–35. https://doi.org/10.3390/idr13040093.
2. Pappagianis D. Epidemiology of coccidioidomycosis. Curr Top Med Mycol. 1988;2:199–238.
3. Heaney AK, Head JR, Broen K, Click K, Taylor J, Balmes JR, et al. Coccidioidomycosis and COVID-19 co-infection, United States, 2020. Emerg Infect Dis. 2021;27:1266–73. https://doi.org/10.3201/eid2705.204661.
4. Chang CC, Senining R, Kim J, Goyal R. An acute pulmonary coccidioidomycosis coinfection in a patient presenting with multifocal pneumonia with COVID-19. J Investig Med High Impact Case Rep. 2020;8:2324709620972244. https://doi.org/10.1177/2324709620972244.
5. Shah AS, Heidari A, Civelli VF, Sharma R, Clark CS, Munoz AD, et al. The coincidence of 2 epidemics, Coccidioidomycosis and SARS-CoV-2: a case report. J Investig Med High Impact Case Rep. 2020;8:2324709620930540. https://doi.org/10.1177/2324709620930540.
6. Chen JC, Wong D, Rabi S, Worswick S, DeClerck B, Gibb J. All that coughs is not COVID-19: a delayed diagnosis of disseminated coccidioidomycosis following severe acute respiratory syndrome coronavirus 2 infection. Open Forum Infect Dis. 2021;8:ofab246. https://doi.org/10.1093/ofid/ofab246.
7. Krauth DS, Jamros CM, Rivard SC, Olson NH, Maves RC. Accelerated progression of disseminated coccidioidomycosis following SARS-CoV-2 infection: a case report. Mil Med. 2021;186:1254–6. https://doi.org/10.1093/milmed/usab132.
8. Nassif EF, Maloney N, Conley AP, Keung EZ. Disseminated coccidioidomycosis following COVID-19 mimicking metastatic thoracic relapse of well-differentiated liposarcoma: a case report. Front Med (Lausanne). 2021;8:715939. https://doi.org/10.3389/fmed.2021.715939.
9. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, et al. Infectious diseases society of america
(IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e112-46. https://doi.org/10.1093/cid/ciw360.

10. Shah DA, James S, Uche IU, Sharer R, Radhakrishnan P. Cutaneous and pulmonary manifestations: virus or coccidioidomycosis. Cureus. 2021;13:e15060. https://doi.org/10.7759/cureus.15060.

11. Zavala A, Stark CM. Chest pain and fever in a healthcare provider during the global coronavirus pandemic. Mil Med. 2021. https://doi.org/10.1093/milmed/usab435.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.